Video

Dr. Molena on Challenges With Endoscopic Resection in Esophageal Cancers

Daniela Molena, MD, discusses what she believes is the Achilles heel of endoscopic resection in patients with esophageal cancer.

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses what she believes is the Achilles heel of endoscopic resection in patients with esophageal cancer.

According to Molena, the challenge today is the inability to predict nodal disease. It’s unknown whether a patient has nodal disease or not, but tumor characteristics can be used to estimate the risk of nodal disease.

If a patient is at high risk of nodal disease, then it is determined that endoscopic resection is not a good option; instead, they should have a more aggressive approach, such as a pharyngectomy. For those who are considered low risk of nodel disease, endoscopic resection is a safe option, Molena explains. For the future, she says it is necessary to find ways to identify nodal disease in patients without having to predict the risk.

View more from the 2019 Gastrointestinal Cancers Symposium

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University